PPARα/δ agonists enhance mitochondrial function and fatty acid oxidation, making them potential treatments for obesity and muscle disorders, including muscular dystrophy and sarcopenia [246]. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.